XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 5,499.4 $ 5,636.7 $ 11,359.2 $ 10,728.9  
Contract liabilities 299.8   299.8   $ 264.6
Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 76.8 153.9 170.0 285.9  
Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 262.0 231.9 529.5 435.5  
Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 290.4 290.7 594.1 542.1  
Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 145.0 $ 102.4 284.7 $ 184.5  
Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contract liabilities $ 40.7   40.7    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     446.4    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     289.0    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     (250.0)    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     $ 180.0    
Royalty Agreement Terms | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations, percentage (up to)     20.00%    
Milestone Payments, Development and Regulatory | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     $ 130.0    
Milestone Payments, Development and Regulatory | Tanezumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     350.0    
Milestone Payments, Development and Regulatory | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     85.0    
Milestone Payments, Sales-based | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     150.0    
Milestone Payments, Sales-based | Tanezumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     1,230.0    
Milestone Payments, Sales-based | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     1,250.0    
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     180.0    
Roche | Milestone Payments, Sales-based | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones (deferred) capitalized     $ 1,030.0